COVID-19 Vaccine: US Drugmaker Pfizer Now Expects US$33.5 Billion Revenue

Pfizer, a US drugmaker Wednesday sharply increased its 2021 projection for revenues tied to its COVID-19 vaccine forecasting generating US$33.5-billion in sales instead of US$26-billion predicted in May.

The company which has partnered with Germany’s BioNTech on the vaccine is estimating to deliver 2.1 billion doses.

Introducing the Pindula News Mobil App
Download from Google Play Store

Pfizer Chief Executive Albert Bourla said more than a billion doses of the vaccine have been delivered, saying “the speed and efficiency of our efforts with BioNTech to help vaccinate the world against COVID-19 have been unprecedented.”

Pfizer said the pre-tax profit margin on the COVID-19 vaccine sales was in the “high-20s” in terms of per cent, the same as the earlier forecast.

The drugmaker reported second-quarter profits of $5.6-billion, up 59 per cent from the year-ago period on a 92 per cent increase in revenues to $19 billion.

Pfizer has launched clinical studies on a possible third dose of the COVID-19 vaccine as a booster shot. Bourla has said such boosters could amount to a “durable” revenue stream for the company.

US health officials have thus far not far backed a third shot for the broad population, but officials are studying the need for a third shot in immunocompromised people.

More: AFP

Join WhatsApp & Telegram News Groups:

WhatsApp Group:

Telegram Group:

Back to top

Write a Comment

Your email address will not be published.

Share Full Post

Nyaradzo logo

RSS Recent Profiles Created

Satisfaction survey
How likely is it that you would recommend Pindula News to a friend or colleague?
SuggestionsHow can we improve?
You have already submitted your feedback. If you would like to add more feedback please write us on